UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K/A
(Amendment No. 2)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 23, 2004
Escalon Medical Corp.
---------------------
(Exact name of registrant as specified in its charter)
Pennsylvania 0-20127 33-0272839
---------------------------- ------------ -------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
575 East Swedesford Road, Suite 100, Wayne, PA 19087
---------------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 610-688-6830
N/A
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Introductory Statement:
----------------------
We are submitting this Form 8-K/A to file revised Exhibit 99.1, the
Independent Auditors' Report of Baker Tilly.
Item 9.01 Financial Statements and Exhibits.
--------- ---------------------------------
(a) Financial Statements of Business Acquired.
Drew Scientific
Independent Auditors' Report
Consolidated Balance Sheet as of March 31, 2004
Consolidated Statement of Income for the Year Ended March 31, 2004
Consolidated Statement of Shareholders' Equity as of March 31, 2004
Consolidated Statement of Cash Flows for the Year Ended March 31, 2004
Notes to Consolidated Financial Statements for the Year Ended March 31, 2004
Independent Auditors' Report
Consolidated Balance Sheet as of March 31, 2003
Consolidated Statement of Income for the Year Ended March 31, 2003
Consolidated Statement of Shareholders' Equity as of March 31, 2003
Consolidated Statement of Cash Flows for the Year Ended March 31, 2003
Notes to Consolidated Financial Statements for the Year Ended March 31, 2003
(b) Unaudited Pro Forma Condensed Consolidated Financial
Statements.
Pro Forma Consolidated Balance Sheet as of June 30, 2004
Pro Forma Consolidated Statement of Operations for Twelve Months Ended
June 30, 2004
Pro Forma Notes to Consolidated Financial Statements for the Year Ended June 30,
2004
(c) Exhibits.
Exhibit No. Exhibit Description
----------- -------------------
23.1 Consent of Baker Tilly, independent auditors. (*)
23.2 Consent of Richard L. Weisheit, P.C., independent auditors.(*)
99.1 Financial Statements of Business Acquired. (*)
99.2 Pro Forma Financial Information. (**)
------------------------
* Filed herewith
** Incorporated by reference to Exhibit 99.2 filed with the Company's
Form 8-K/A on October 10, 2004.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ESCALON MEDICAL CORP.
Date: June 21, 2006 By: /s/ Richard J. DePiano
--------------------------------
Richard J. DePiano
Chairman and
Chief Executive Officer